The invention relates to polyguanidine silicate which can be obtained by reacting a polymeric guanidine salt present in aqueous solution with an aqueous solution of a sodium and/or potassium silicate.
A liposomal drug composition comprising: a dimeric or polymeric guanidine derivative or a pharmaceutically acceptable salt thereof as drug substance, and a lipid modified by polyethylene glycole (PEG). The drug composition have cytostatic and antimicrobial activity.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The invention relates to a medicament containing a solid microbiocidally active polymer mixture comprising a first polymer as a matrix wherein a second polymer is introduced. The second polymer is a polymer guanidine or biguanidine derivative.
The invention relates to a microbiocidally active polymer mixture comprising a first polymer as a matrix wherein a second polymer is introduced. The second polymer is a polymer guanidine or biguanidine derivative. Said microbiocidally active polymer mixture is characterised in that it is a powder.
The invention relates to a complex containing (a) a polymeric guanidine and gelatine or (b) a polymeric guanidine and a polysaccharide. Said polymeric guanidine is preferably a condensation product which can be obtained by reacting guanidine or a salt thereof with an alkylene diamine and/or an oxyalkylene diamine.